Review Article

Anti- and Protumorigenic Effects of PPAR\(\gamma\) in Lung Cancer Progression: A Double-Edged Sword

Howard Li,\(^1,2\) Mary C. M. Weiser-Evans,\(^3\) and Raphael Nemenoff\(^3,4\)

\(^1\) Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
\(^2\) Pulmonary and Critical Care Section, Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO 80220, USA
\(^3\) Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
\(^4\) Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado, Anschutz Medical Campus, C-281 12700 East 19th Avenue, Aurora, CO 80045, USA

Correspondence should be addressed to Raphael Nemenoff, raphael.nemenoff@ucdenver.edu

Received 29 February 2012; Accepted 9 July 2012

Peroxisome proliferator-activated receptor-\(\gamma\) (PPAR\(\gamma\)) is a member of the nuclear receptor superfamily of ligand-activated transcription factors that plays an important role in the control of gene expression linked to a variety of physiological processes, including cancer. Ligands for PPAR\(\gamma\) include naturally occurring fatty acids and the thiazolidinedione class of antidiabetic drugs. Activation of PPAR\(\gamma\) in a variety of cancer cells leads to inhibition of growth, decreased invasiveness, reduced production of proinflammatory cytokines, and promotion of a more differentiated phenotype. However, systemic activation of PPAR\(\gamma\) has been reported to be protumorigenic in some in vitro systems and in vivo models. Here, we review the available data that implicate PPAR\(\gamma\) in lung carcinogenesis and highlight the challenges of targeting PPAR\(\gamma\) in lung cancer treatments.

1. Introduction

Lung cancer is the most common cause of cancer-related deaths in men and women worldwide and is responsible for 1.4 million deaths annually [1]. Each year, more people die of lung cancer than breast, colon, and prostate cancers combined. Despite improvements in surgical techniques and combined therapies, lung cancer remains a disease with a dismal prognosis. Although one-year all-stage survival increased from 32% in 1973 to 41% in 1994, overall five-year survival has remained unchanged at 14%. The five-year survival rate is 53% for cases detected when the disease is still localized, but only 15% of lung cancers are diagnosed at this early stage [2]. These data underscore the need to develop new therapeutic approaches to target lung cancer progression and metastasis.

During the past 25 years, cancer research has made great progress in defining pathways involved in the transformation of “normal” epithelial cells to cancer cells. These studies have largely focused on the identification of somatic mutations resulting in the activation of oncogenes and the inhibition of tumor suppressor pathways. However, the pathways mediating the conversion of a cancer cell to a metastatic cancer cell remain poorly understood. In addition, it has become apparent during the last decade that progression of solid tumors to metastatic disease involves not just changes in the transformed epithelia itself, but also critical changes in the surrounding stroma, designated the tumor microenvironment (TME) [3]. Changes in the TME have been observed for a long time, in particular, an association between chronic inflammation and tumor development [4]. However, the mechanistic pathways whereby stromal cells contribute to cancer progression are only now beginning to be defined. These effects include changes in tumor angiogenesis [5], alterations in immune regulation [6], and changes in fibrosis and mechanical properties of the TME [7]. Each of these changes is mediated through complex interactions that involve crosstalk between cancer cells and multiple other cell types, including vascular cells, innate and adaptive immune cells, and fibroblasts. Defining this crosstalk at the molecular
level will require the development of novel, more complex in vitro systems along with the use of genetic animal models.

The development of new therapeutic agents specifically designed to target progression of advanced metastatic disease distinct from tumor initiation raises several issues regarding the role of the TME in cancer progression. Importantly, activation of a specific pathway in different cell types might have opposing effects on tumor progression. This has been elegantly demonstrated in the case of the transcription factor NF-κB. Work by Karin et al. demonstrated that in the setting of hepatocellular carcinoma, activation of NF-κB in hepatocytes is protective against developing cancer [8, 9], whereas activation in macrophages promotes cancer progression [10]. These studies show paradoxically that the same pathway activated in different cell types exerts distinct and sometimes opposing roles on cancer progression. Given the complex interactions between the TME and cancer cells, understanding cell type-specific effects will be crucial when the use of systemically delivered therapeutics is considered.

Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-activated transcription factors [11]. Activation of this receptor has been shown to be critical in adipocyte development. Importantly, PPARγ is the target of the thiazolidinedione (TZD) class of drugs including rosiglitazone and pioglitazone. These agents have been employed for treatment of diabetes and act at least in part through sensitization of adipocytes to insulin. There has been great interest in this class of agents as chemopreventive and chemotherapeutic agents in a wide variety of cancers, including lung cancer [12, 13]. A large body of literature has demonstrated that direct activation of PPARγ in a variety of cancer cells leads to inhibition of growth, decreased invasiveness, reduced production of proinflammatory cytokines, and in many cases promotion of a more differentiated phenotype. Use of this agent would, therefore, be predicted to be successful as a chemopreventive agent. However, systemic activation of PPARγ has been reported to be protumorigenic in some experimental settings and in vivo models. This paper summarizes the available data that implicate PPARγ in lung carcinogenesis and highlights the challenges of targeting PPARγ in lung cancer treatments. We will also focus on how activation of this pathway in stromal cells may impact tumor progression.

2. Mechanisms of PPARγ Action

PPARγ is a member of the PPAR subfamily of nuclear receptors. Two isoforms have been identified in humans, PPARγ1 and PPARγ2. Whereas PPARγ2 is expressed primarily in adipose tissue [14], PPARγ1 is expressed in a broad range of tissues as well as several cancer cell lines, including lung cancer [15]. Similar to other nuclear receptors, PPARγ consists of a DNA-binding domain and a ligand-binding domain connected by a hinge region [16]. There are two activation domains: AF-1 at the amino terminal and AF-2 at the carboxyl terminal. PPARγ is a ligand-activated transcription factor that functions as a heterodimer with the retinoid X receptor to bind specific PPAR response elements (PPAR-RE). The consensus PPAR-RE site consists of a direct repeat of the sequence AGGTCA separated by a single nucleotide, which is designated the DR-1 site. Ligand binding causes a conformational change that leads to the release of coresspressors and the binding of coactivators, resulting in increased transcription of target genes.

Naturally occurring substances, such as polyunsaturated fatty acids and eicosanoids, are thought to serve as endogenous PPARγ ligands. In particular, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) has been shown to activate PPARγ specifically with micromolar affinity [17]. The lipoxigenase products of linoleic acid 9- and 13-HODE also have micromolar affinities for PPARγ [18]. However, it is unclear whether these agents are regulators of PPARγ in vivo, and studies have shown that endogenous levels of 15d-PGJ2 fail to change during adipocyte differentiation [19]. Synthetic activators of PPARγ include the thiazolidinedione class of antidiabetic agents, such as troglitazone, rosiglitazone, and pioglitazone [20]. These compounds have effects on insulin-sensitivity and adipogenesis, which are mediated at least in part through PPARγ activation. Nonsteroidal anti-inflammatory drugs also activate PPARγ, albeit at concentrations higher than those required for cyclooxygenase inhibition [21].

Although TZDs directly activate PPARγ, several reports suggest that stimulation of “off-target” pathways impacts their therapeutic effects. For example, Han and Roman showed that rosiglitazone inhibits Akt phosphorylation through PPARγ-dependent induction of PTEN expression, but induction of AMPK phosphorylation and subsequent inhibition of p70S6K phosphorylation by rosiglitazone occur through PPARγ-independent signals [22]. Even with overexpression of dominant-negative PPARγ, pioglitazone and rosiglitazone suppressed PGE2 in human non-small cell lung cancer (NSCLC) A549 cells, suggesting a PPARγ-independent effect of TZDs. Similarly, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by TZDs was shown to be mediated through PPARγ-independent induction of death receptor-5 and downregulation of c-FLIP in NSCLC cell lines [23]. Early growth response-1 transcription factor was shown to be induced by troglitazone but not by other PPARγ ligands, suggesting the proapoptotic effects of troglitazone may be independent of PPARγ. Moreover, PPARγ can directly bind to other transcription factors, including NF-κB and Sp1 [24] leading to repression of these pathways. Therefore, the ability to engage or otherwise control regulatory elements distinct from classic PPAR response element sites complicates the spectrum of genes that may be controlled by PPARγ [25] and poses an important barrier to understanding the biological role of PPARγ in lung cancer.

3. Clinical Associations of PPARγ with Lung Cancer

Preclinical studies using PPARγ agonists, specifically TZDs such as rosiglitazone and pioglitazone, have been shown to
inhibit tumor growth in many types of cancer. TZDs inhibit the growth of colon cancer cell lines in vitro [26–28] and in xenograft models [29] as well as growth of breast cancer [30–32] and prostate cancer cells [33–35]. In lung cancer, decreased expression of PPARγ was correlated with poor prognosis in samples from human lung tumors [36]. Genetic variants in the PPARγ gene have also been identified that are associated with a decreased risk for lung cancer [37]. Thus, PPARγ expression may serve as a prognostic marker in lung cancer and polymorphisms in the PPARγ gene may be a way to identify patients with increased risk for lung cancer. More recently, a retrospective study out of the Veterans Affairs (VA) system of nearly 88,000 individuals demonstrated a 33% reduction in lung cancer risk among TZD users compared with nonusers [38]. The risk reduction for colorectal and prostate cancers did not reach statistical significance, suggesting the beneficial effects of TZD use may be specific for lung cancer. Collectively, these data suggest that the PPARγ pathway is a potential target for treatment of lung cancer. Indeed, as discussed below, several chemoprevention trials have been initiated that incorporate TZDs. Importantly, however, information regarding the effects of TZDs on lung cancer progression and metastasis is lacking. In fact, in the retrospective VA study discussed above, patients who had an established diagnosis of cancer were excluded from the study.

Several clinical trials have been initiated that incorporate TZDs for prevention of head and neck cancer or lung cancer. One phase II trial studying the effectiveness of pioglitazone in preventing head and neck cancer in individuals with oral leukoplakia showed that 71% of individuals treated with pioglitazone had complete or partial response, 10% had stable disease, and 19% had progressive disease (ClinicalTrials.gov NCT00099021). A major limitation of this study was early termination leading to small numbers of participants analyzed (21 total). However, these promising results have lead to a large collaborative trial that is currently recruiting participants looking at the effects of pioglitazone on oral premalignant lesions and the risk of head and neck cancer (ClinicalTrials.gov NCT00951379). Similarly, a clinical trial evaluating the chemopreventive ability of pioglitazone in subjects at risk for lung cancer is currently recruiting participants (ClinicalTrials.gov NCT00780234). However, an ongoing concern regarding these trials is the association of chronic TZD treatment with increased adverse cardiac events [39] and risk of bladder cancer [40, 41].

4. Effects of PPARγ in Lung Cancer Cells

4.1. Antitumorigenic Effects of PPARγ. Based on histological characteristics, lung cancer is classified as either small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), with NSCLC accounting for nearly 85% of all lung cancer cases. PPARγ is expressed in both SCLC and NSCLC [42]. Several studies have demonstrated that activation of PPARγ inhibits growth of multiple human NSCLC cell lines. For example, molecular overexpression of PPARγ in human NSCLC cell lines inhibited anchorage-independent growth and invasiveness, promoted differentiation, and increased E-cadherin expression (a marker for sensitivity to tyrosine kinase inhibition) [43]. These changes were associated with cyclooxygenase 2 (COX-2) inhibition and reduced NF-κB activity, resulting in decreased production of cytokines, such as IL-6, IL-8, and vascular endothelial growth factor (VEGF). The effects of pharmacological activation of PPARγ using TZDs on human NSCLC lines have also been examined in several studies. Similar to molecular overexpression, TZD activation of PPARγ promotes a more highly differentiated phenotype in multiple human NSCLC lines [44]. In addition, treatment of human NSCLC lines with PPARγ ligands resulted in growth arrest, loss of capacity for anchorage-independent growth, and decreased activity and expression of matrix metalloproteinase (MMP) 2 [44], as well as apoptosis induction [23, 45, 46].

COX-2 is an enzyme involved in the synthesis of prostaglandins that has been linked to the development of cancer (reviewed in [47]). Our laboratory has shown that activation of PPARγ in NSCLC inhibited expression of COX-2 protein at the level of transcription [48]. In this study, suppression of COX-2 was mediated through increased PTEN activity, leading to decreased levels of phospho-Akt and inhibition of NF-κB activity. One of the major metabolites of COX-2, prostaglandin E2 (PGE2), signals through G protein-coupled receptors designated EP receptors, which have also been implicated in the pathogenesis of NSCLC [49, 50]. PGE2 has also been shown to stimulate NSCLC proliferation via EP2 receptors [51]. In the study by Han and Roman, PPARγ ligands inhibited human NSCLC growth by decreasing the expression of EP2 receptors through Erk signaling and both PPARα-dependent and -independent pathways. More recently, the TZDs pioglitazone and rosiglitazone have been shown to inhibit PGE2 production in NSCLC cells via a COX-2 independent pathway by upregulation of 15-hydroxyprostaglandin dehydrogenase [52]. Our laboratory has also shown that the TZD rosiglitazone specifically decreased expression of Snail [53], which is a transcription factor that regulates epithelial-mesenchymal transition. Suppression of Snail using short hairpin RNA silencing mimicked the effects of PPARγ activation by inhibiting anchorage-independent growth, promoting acinar formation in three-dimensional culture, and inhibiting invasiveness. Suppression of Snail was also associated with the increased expression of E-cadherin and decreased expression of COX-2 and MMPs.

Recently, preclinical studies have demonstrated an antitumorigenic role of PPARγ. Treatment of SCID mice bearing human NSCLC A549 tumors with the TZDs troglitazone or pioglitazone inhibited primary tumor growth and significantly inhibited the number of spontaneous lung metastatic lesions [54]. In addition to affecting the biology of the tumor cells themselves, activation of PPARγ also reduced production of the tumor cell-derived cytokines CXCL8, CXCL5, and CXCL1, which are critical for angiogenesis and tumor-stromal interactions [55]. Work from our laboratory showed that in nude rats, orthotopic implantation of human NSCLC H2122 cells that overexpressed PPARγ inhibited tumor growth and metastasis, and prolonged survival compared
to implantation of control H2122 cells [43]. In addition, we have shown that transgenic mice overexpressing PPARγ in lung distal epithelium are protected against developing tumors in a chemical carcinogenic model [48]. Collectively, these studies suggest that selective activation of PPARγ in NSCLC cells is protective against lung cancer initiation, progression, and metastasis.

4.2. Protumorigenic Effects of PPARγ. Although emerging data suggest that PPARγ and PPARδ ligands exert antitumorigenic effects on cancer cells, there is evidence that activation of PPARγ may also have deleterious, protumorigenic effects. In contrast to lung cancer, a survey of various tumors revealed that PPARγ is generally overexpressed in liposarcoma, colon, breast, and prostate carcinomas [56, 57]. In mouse models of colon cancer, activation of PPARγ by the TZD troglitazone increased the frequency and size of colon tumors in both C57BL/6-APCΔmin/+ mice [58, 59] and wild-type C57BL/6 mice [60]. Similar to lung cancer cell lines, breast cancer cell lines undergo growth arrest and differentiation when treated with synthetic PPARγ ligands [30, 61]. However, transgenic mice expressing constitutively active PPARγ in the mammary gland developed tumors at an accelerated rate compared to wild-type controls [62]. Interestingly, tumors in the PPARγ overexpressing mice were more differentiated despite the more rapid rate of tumorigenesis. In high-grade hepatocellular carcinoma cell lines, treatment with PPARγ antagonists has been shown to inhibit cell growth, colony formation, migration, and invasion [63]. Inhibition of PPARγ activity has also been shown to suppress pancreatic cancer cell motility [64]. More recently, PPARγ protein expression has been linked with the aggressiveness of thyroid cancer cells [65]. PPARγ levels are elevated in cells derived from undifferentiated (anaplastic) thyroid cancer. Depletion of PPARγ in anaplastic thyroid cancer cells resulted in decreased cell growth and invasiveness in vitro. Moreover, PPARγ-depleted cells grew more slowly in vivo in flank and orthotopic thyroid tumors. Conversely, when PPARγ was overexpressed in more differentiated thyroid cancer cells, there was increased growth and invasiveness in vitro.

In the human NSCLC line H460, which exhibits multidrug resistance, PPARγ binding to both Smad3 and p-Smad3 disrupted p-Smad3-mediated mitotic arrest and growth inhibition, eventually leading to transforming growth factor-beta (TGFβ) resistance [66]. More recently, Ahn et al. [67] demonstrated that repression of PPARγ by mitogen-activated protein kinase kinase-4 suppressed lung cancer cell invasion. In this study, knockdown of PPARγ with shRNA or treatment with the PPARγ antagonist T0070907 blocked murine lung cancer cell invasion. Conversely, forced expression of PPARγ enhanced murine lung cancer cell invasion. Collectively, these studies suggest that increased PPARγ signaling can also serve as a tumor promoter in lung cancer. Thus, activation of PPARγ in lung and other cancers can lead to either tumor suppressive or promoting responses, based on the set of conditions encountered (see Figure 1).

5. Effects of PPARγ Activation in the Tumor Microenvironment

The role of the TME in mediating tumor progression has become evident over the past few years [3]. In contrast to cancer initiation, which is largely mediated through alterations in transformed epithelial cells, tumor progression and metastasis involves critical interactions between the tumor and the microenvironment. Interactions between tumor cells, vascular cells, fibroblasts, and immune cells establish a local microenvironment that suppresses the immune response and promotes cancer progression. Cancer progression involves numerous changes, including tumor angiogenesis and the acquisition of a more aggressive cancer cell phenotype. In addition to epithelial cells, PPARγ is expressed in immune cells, endothelial cells and fibroblasts in and surrounding lung tumors [42]. However, the role of PPARγ in the tumor microenvironment on cancer progression has not been well studied. Here, we will focus on how activation of PPARγ in different stromal cells may impact tumor progression (see Figure 2).

5.1. Tumor-Associated Macrophages. Macrophages play a complex role in cancer progression [68–70]. Although macrophages can mediate direct cytotoxic effects on tumors, tumor-associated macrophages (TAMs) have been implicated in the promotion of tumor growth and metastasis. Specifically, TAMs can produce epidermal growth factor, which stimulates migration of tumor cells [71]. TAMs produce many proteases, including cathepsins, matrix metalloproteinases (MMPs), and serine proteases [72]. These proteases destroy the matrix to allow the escape of tumor cells from the confines of the basement membrane and migration of tumor cells through the dense stroma. TAMs are also major contributors to the angiogenic switch, which is a dramatic enhancement of vascular density that accelerates the transition to malignancy [73]. TAM-mediated angiogenesis occurs through increased accumulation of VEGF in the TME, either through production of VEGF [74, 75] or activation of MMP9, which releases VEGF from extracellular depots [76]. Thus, TAMs play a significant role in vascular remodeling as tumors progress to late carcinoma stages [77]. In addition, TAMs have been shown to affect the adaptive immune system. Production of IL-10 by TAMs inhibits cytotoxic T cell responses, resulting in expression of programmed death ligand (PD)-L1 and CCL22 and regulation of regulatory T cell influx. TAMs also suppress immune responses through synthesis of PGES and TGFβ [78]. Finally, TAMs play a critical role in metastasis by aiding tumor cell extravasation and promoting tumor cell survival in the circulation, thereby enhancing metastatic cell seeding efficiency [79].

Macrophages have been shown to have different activation states. “Classically” activated macrophages are educated by IFN-γ and LPS and are characterized by an IL-12high, IL-10low phenotype [80]. In general, classically activated macrophages defend the host from viral and microbial infections, fight against tumors, produce high amounts of
Figure 1: Effector pathways for PPARγ in NSCLC. Antitumorigenic effects of PPARγ on NSCLC cells (top half, shaded): PPARγ-mediated suppression of COX-2 expression in NSCLC leads to decreased PGE2 production, which inhibits NSCLC proliferation. PPARγ can also increase expression and enzymatic activity of PTEN. This leads to inhibition of Akt activation (pAkt), and subsequent decreased activity of the transcription factor NF-κB. NF-κB is a transcription factor that is critical for the production of proangiogenic and proinflammatory cytokines, such as IL-6, IL-8 and VEGF. Decreased production of these factors would be expected to block tumor angiogenesis. PPARγ-mediated suppression of members of the Snail family of transcription factors, such as Snail, Zeb, or Twist, would lead to derepression of E-cadherin expression and promote the epithelial phenotype, leading to decreased migration and invasiveness.

Protumorigenic

Tumor cell invasion (through MKK4 kinase-dependent pathway)

NF-κB

Epithelial differentiation (E-cadherin)

Cytokines (IL-6, IL-8, VEGF)

Proliferation

Migration/invasiveness

↓ PGE2

↓ COX-2

↓ p-Akt

↓ PTEN

↓ p-Smad3 nuclear accumulation

↓ Resistance to TGFβ-mediated mitoinhibition

↓ Tumor cell invasion

PPARγ

Inflammatory cytokines, and activate the immune response. In contrast, “alternatively” activated macrophages are educated by IL-4 and IL-13 and are characterized by an IL-12low, IL-10high phenotype. Alternatively activated macrophages promote scavenging of debris, angiogenesis, and remodeling and repair of wounded or damaged tissues. Importantly, alternatively activated macrophages attenuate the inflammatory response by downregulating innate immunity. Changes in macrophage phenotype have been reported during the initiation and progression of chemically induced lung tumors [81] with TAMs exhibiting an alternatively activated phenotype [82].

Interestingly, systemic administration of TZDs has been shown to be protective against the progression of atherosclerosis. PPARγ activation in human atherosclerotic lesions primes human monocytes into alternatively activated macrophages [83, 84] thus enhancing the anti-inflammatory properties of these macrophages leading to plaque stabilization. PPARγ controls the inflammatory response of macrophages by interfering with proinflammatory signaling pathways such as AP-1, NF-κB, and STAT-3 [85]. Consistent with these effects, targeted deletion of PPARγ in macrophages has been shown to increase atherosclerosis [86]. Thus, the antiatherogenic effects of PPARγ are mediated at least in part by alternative activation of macrophages, which leads to resolution of inflammation. However, similar to macrophages residing in PPARγ-activated atherosclerotic lesions, TAMs also exhibit an alternatively activated, anti-inflammatory phenotype [68, 82]. Alternative activation of macrophages in the setting of cancer progression may...
Figure 2: The role of PPARγ signaling in the tumor microenvironment. Activation of PPARγ in macrophages promotes a tumor-associated phenotype, which leads to increased tumor angiogenesis, matrix breakdown, and tumor cell motility. Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis in mice. Similarly, activation of PPARγ in the tumor microenvironment leads to generation of Tregs and inhibition of host T-cell antitumor activity, resulting in an immunosuppressive environment that promotes tumor progression. TZDs have been shown to inhibit angiogenesis by decreasing endothelial cell proliferation and migration, inducing endothelial cell apoptosis, and by decreasing VEGF production. However, activation of PPARγ by 15d-PGJ2 has been shown to upregulate VEGF expression in human breast cancer cells, which may contribute to increased tumor angiogenesis. Finally, PPARγ expression has been shown to be upregulated in stromal myofibroblasts surrounding colon adenocarcinomas, which promote proliferation, mobility, and invasion of tumor cells.

therefore promote tumor progression by facilitating angiogenesis, matrix breakdown, and tumor cell motility. Indeed, data from our laboratory indicate that macrophage-specific PPARγ plays a critical role in the ability of cancer cells to educate macrophages into an alternatively activated phenotype [87]. Whereas selective activation of PPARγ in human NSCLC cells leads to fewer metastases and increased survival in nude athymic rats [43], systemic activation of PPARγ in both cancer cells and the tumor microenvironment by pioglitazone leads to increased tumor progression and metastasis in an orthotopic mouse model of lung cancer. Moreover, targeted deletion of PPARγ in myeloid cells using loxP recombination promoted significantly fewer metastases in our orthotopic model [87]. We believe these findings indicate PPARγ in the tumor microenvironment, and in particular TAMs, plays a critical role in lung cancer metastasis.

5.2. T Lymphocytes. Regulatory T cells (Tregs) found in lung tumors have been shown to inhibit the host immune response and contribute to the progression of cancer. Elimination of CD4+CD25+ Tregs elicited immune responses to syngeneic tumors in mice, leading to the eradication of the tumors [88]. Human lung tumors have been shown to contain large numbers of CD4+CD25+ Tregs, which have constitutively high-level expression of CD152 (CTLA-4). These Tregs mediated potent inhibition of autologous T cell proliferation but failed to inhibit the proliferation of allogeneic T cells [89]. Tumors formed by the CT26 colon carcinoma-derived cell line in BALB/c mice facilitated the induction or recruitment of CD4+ Tregs that secreted IL-10 and TGFβ and suppressed effector CD8+ T cell responses [90]. Thus, Tregs could be responsible for inhibiting host T-cell activity against tumor-associated antigens.

IL-2 is a T cell growth factor that augments NK cell cytolytic activity, contributes to the development of Tregs, and regulates the proliferation and apoptosis of activated T cells. The PPARγ ligands troglitazone and 15d-PGJ2 inhibit IL-2 production in human peripheral blood T-cells in a dose-dependent manner [91]. Similarly, 15d-PGJ2 and ciglitazone inhibit proliferation and IL-2 secretion in murine helper T cells. PPARγ activation also increases retinoic acid secretion from murine splenic dendritic cells, leading to induction of Tregs in the periphery [92]. Thus, activation of PPARγ in the tumor microenvironment appears to lead to
5.5. Hepatic Stellate Cells. Because the liver is a common site of metastases for many cancers, including lung, it has been hypothesized that the liver provides a prometastatic microenvironment for cancer cells, and that hepatic stellate cells (HSCs) are the predominant cell type involved with establishment of this microenvironment (reviewed in [103]). In response to paracrine factors released by cancer cells, HSCs transdifferentiate into myofibroblasts that can promote tumor growth. Activated HSCs produced growth factors and cytokines which enhance the proliferation and migration of tumor cells [104]. HSCs also promoted tumor angiogenesis by producing factors such as VEGF and angiopoietin [105–108] and have been shown to inhibit T cell proliferation and induce T cell apoptosis [109, 110], which suggests they may suppress the antitumor immune response in the liver. PPARγ is expressed in quiescent HSCs, and its expression and activity decrease in HSC activation both in vitro and in vivo [111–113]. PPARγ agonists inhibited HSC proliferation and chemotaxis, and expression of monocyte chemotactic protein-1 at the gene and protein levels in HSCs [111]. Similarly, forced expression of PPARγ reversed culture-activated HSCs to a quiescent phenotype [114, 115]. Thus, maintenance of the quiescent state of HSC appears to require PPARγ, and depletion of PPARγ may be required for activation of HSCs. Although the role of HSC-specific PPARγ in liver metastasis has not been established, it is likely that PPARγ signaling is involved in the formation of a prometastatic microenvironment.

5.6. Other Immune Cells in the Tumor Microenvironment. The tumor microenvironment is comprised of a variety of inflammatory cells, including dendritic cells, natural killer (NK) cells, myeloid-derived suppressor cells, neutrophils, and eosinophils. A recent study suggests that dendritic cells initiate antitumoral T cell responses and are pivotal for the establishment of an in situ efficient immune reaction in NSCLC [116]. Of note, PPARγ has been shown to modulate the inflammatory response of human dendritic cells, with ligand-induced activation of PPARγ by rosiglitazone resulting in enhanced phagocytosis of apoptotic neutrophils [117]. NK cells have also been implicated in the immune defense against tumors [118]. The PPARγ ligands 15d-PGJ2 and ciglitazone have been shown to reduce IFN-γ production and inhibit cytolytic activity of human NK cells [119]. The role of PPARγ in other cell types in the tumor microenvironment, however, is largely unknown.

6. “On-Target” versus “Off-Target” Effects of TZDs

A critical issue in interpreting studies of PPARγ that utilize TZDs and other PPARγ agonists is determining whether the effects of these agents are mediated through PPARγ-dependent versus PPARγ-independent pathways. One approach is to compare the responses of cells to TZDs with overexpression of full-length PPARγ. For example, overexpression of PPARγ in NSCLC cells had no significant effects on cell proliferation, as seen with TZD treatment, but instead had selective effects on anchorage-independent growth and invasiveness [48]. Specific PPARγ antagonists can also be used to identify PPARγ-specific effects of TZDs. Han and Roman showed that the specific PPARγ antagonist GW9662 failed to affect rosiglitazone-mediated phosphorylation of AMP-activated protein kinase α in NSCLC cells, which indicate these effects of rosiglitazone are PPARγ-independent [22]. Transfection of small interfering RNA
(siRNA) or small hairpin RNA (shRNA) to silence PPARγ.

Defining the off-target effects of TZDs such as rosiglitazone and pioglitazone will be critical in developing new therapeutic agents. In particular, it will be important to determine whether adverse effects of these agents (e.g., increased cardiovascular events or increased incidence of bladder cancer) are mediated through PPARγ-dependent or -independent mechanisms. Newer generation PPARγ activators may provide more selective engagement of PPARγ-dependent antitumorigenic pathways while minimizing adverse PPARγ-independent cardiovascular or proinflammatory effects.

7. Conclusions and Implications for Therapy

The studies reviewed above implicate PPARγ in lung cancer cell biology. Many studies indicate that activation of PPARγ in cancer cells leads to differentiation and induction of apoptosis, which has resulted in considerable excitement regarding the use of TZDs and PPARγ agonists for the prevention and treatment of lung cancer. Tumor-promoting effects of PPARγ and PPARγ agonists need further investigation, and the effects of PPARγ activation on lung cancer cells may vary depending on tumor type or stage. In many of the studies reviewed above, it is unclear whether the biological responses of PPARγ agonists are mediated through “on-target” activation of PPARγ, or through other “off-target” effects. A strategy to address this issue is the use of molecular approaches, either by overexpressing or silencing PPARγ in cancer cells to complement studies with pharmacological agents. Genetic mouse models using targeted knockouts of PPARγ in either cancer cells or cells in the tumor microenvironment will also be informative. There will also be concerns regarding the safety of TZDs, especially since rosiglitazone use has been associated with an elevated risk of heart attacks [121], and pioglitazone use may be associated with an increased risk of bladder cancer [40, 41]. Thus, defining the molecular targets of TZDs that mediate specific responses in lung cancer cells will be critical for the development of future therapeutic interventions. Finally, the role of PPARγ in cells in the tumor microenvironment remains unclear. Indeed, activation of PPARγ in macrophages, Tregs, and NK cells may lead to an immunosuppressive environment that promotes tumor progression. Thus, as our laboratory has demonstrated, activation of PPARγ in both tumor cells and in cells in the tumor microenvironment by systemic agents will likely have opposing effects on tumor progression. Agents that selectively activate PPARγ in epithelial and cancer cells would therefore be very attractive for the prevention and treatment of lung cancer.

References

[1] Global Cancer Facts & Figures 2007, American Cancer Society, Atlanta, Ga, USA, 2007.
[2] “SEER Cancer Statistics Review, 1975–2008,” 2011, http://seer.cancer.gov/csr/1975_2008/
[3] P. A. Kenny, G. Y. Lee, and M. J. Bissell, “Targeting the tumor microenvironment,” Frontiers in Bioscience, vol. 12, pp. 3468–3474, 2007.
[4] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, Inflammation, and Cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010.
[5] S. M. Weis and D. A. Cheresh, “Tumor angiogenesis: molecular pathways and therapeutic targets,” Nature Medicine, vol. 17, no. 11, pp. 1359–1370, 2011.
[6] B. Milcik, B. Bindia, F. Pagès, and J. Galon, “Tumor immunosurveillance in human cancers,” Cancer and Metastasis Reviews, vol. 30, no. 1, pp. 5–12, 2011.
[7] A. C. Shieh, “Biomechanical forces shape the tumor microenvironment,” Annals of Biomedical Engineering, vol. 39, no. 5, pp. 1379–1389, 2011.
[8] S. Maeda, H. Kamata, J. L. Luo, H. Leffert, and M. Karin, “IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis,” Cell, vol. 121, no. 7, pp. 977–990, 2005.
[9] T. Sakurai, G. He, A. Matsuzawa et al., “Hepatocyte necrosis induced by oxidative stress and IL-1α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis,” Cancer Cell, vol. 14, no. 2, pp. 156–165, 2008.
[10] W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production,” Science, vol. 317, no. 5834, pp. 121–124, 2007.
[11] P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008.
[12] V. G. Keshamouni, S. Han, and J. Roman, “Peroxisome proliferator-activated receptors in lung cancer,” PPAR Research, vol. 2007, Article ID 90289, 10 pages, 2007.
[13] R. A. Nemenoff, M. Weiser-Evans, and R. A. Winn, “Activation and molecular targets of peroxisome proliferator-activated receptor-γ ligands in lung cancer,” PPAR Research, vol. 2008, Article ID 156875, 8 pages, 2008.
[14] L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997.
[15] C. D. Alred and M. W. Kilgore, “Selective activation of PPARγ in breast, colon, and lung cancer cell lines,” Molecular and Cellular Endocrinology, vol. 235, no. 1–2, pp. 21–29, 2005.
[16] V. Laudet, “Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor,” Journal of Molecular Endocrinology, vol. 19, no. 3, pp. 207–226, 1997.
[17] S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995.
[18] L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998.
[19] L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “Biosynthesis of 15-deoxy-
delta12, 14-PGJ2 and the ligation of PPARgamma,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 945–955, 2003.

[20] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkinson, T. M. Willson, and S. A. Kliwer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPARy),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.

[21] J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliwer, “Peroxisome proliferator-activated rece-
tors α and γ are activated by indomethacin and other non-
steroidal anti-inflammatory drugs,” The Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997.

[22] S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARy-dependent and
PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006.

[23] W. Zou, X. Liu, P. Yue, F. R. Khuri, and S. Y. Sun, “PPARγ ligands enhance TRAIL-induced apoptosis through DR5
upregulation and c-FLIP downregulation in human lung cancer cells,” Cancer Biology and Therapy, vol. 6, no. 1, pp.
99–106, 2007.

[24] E. Chen, M. Wang, J. P. O’Connor, M. He, T. Tripathi, and L. E. Harrison, “Phosphorylation of PPARγ by active ERK1/2
leads to its physical association with Nrf6 and inhibition of NF-kB,” Journal of Cellular Biochemistry, vol. 90, no. 4, pp.
732–744, 2003.

[25] C. A. Argmann, T. A. Cock, and J. Auwerx, “Peroxisome proliferator-activated receptor y: the more the merrier?”
European Journal of Clinical Investigation, vol. 35, no. 2, pp. 82–92, 2005.

[26] S. Kitamura, Y. Miyazaki, S. Hiraoka et al., “PPARγ agonists inhibit cell growth and suppress the expression of cyclin
D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells,” International Journal of Cancer, vol. 94, no. 3,
pp. 335–342, 2001.

[27] J. Shao, H. Sheng, and R. N. DuBois, “Peroxisome proliferator-activated receptors modulate K-Ras-mediated
transformation of intestinal epithelial cells,” Cancer Research, vol. 62, no. 11, pp. 3282–3288, 2002.

[28] A. J. Kim, K. S. Park, H. I. Kim et al., “Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human
colorectal cancer cells,” Cancer Letters, vol. 179, no. 2, pp. 185–195, 2002.

[29] P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through
PPARγ,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998.

[30] E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentia-
tion of human breast cancer through PPARγ,” Molecular Cell,
vol. 1, no. 3, pp. 465–470, 1998.

[31] F. Yin, S. Wåkino, Z. Liu et al., “Troglitazone inhibits growth of
MCF-7 breast carcinoma cells by targeting G1 cell cycle
regulators,” Biochemical and Biophysical Research Communica-
tions, vol. 286, no. 5, pp. 916–922, 2001.

[32] C. E. Clay, A. M. Namen, G. I. Atsumi et al., “Influence of J
series prostaglandins on apoptosis and tumorigenesis of
breast cancer cells,” Carcinogenesis, vol. 20, no. 10, pp. 1905–
1911, 1999.

[33] E. Mueller, M. Smith, P. Sarraf et al., “Effects of ligand activa-
tion of peroxisome proliferator-activated receptor γ in
human prostate cancer,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 97, no. 20, pp.
10990–10995, 2000.

[34] J. I. Hisatake, T. Ikezoe, M. Carey, S. Holden, S. Tomoyasu,
and H. P. Koehler, “Down-regulation of prostate-specific
antigen expression by ligands for peroxisome proliferator-
activated receptor γ in human prostate cancer,” Cancer Research,
vol. 60, no. 19, pp. 5494–5498, 2000.

[35] T. Kubota, K. Koshizuka, E. A. Williamson et al., “Ligand for
peroxisome proliferator-activated receptor γ (Troglitazone)
has potent antitumor effect against human prostate cancer
both in vitro and in vivo,” Cancer Research, vol. 58, no. 15,
pp. 3344–3352, 1998.

[36] H. Sasaki, M. Tanahashi, H. Yukiue et al., “Decreased peroxi-
some proliferator-activated receptor gamma gene expression
was correlated with poor prognosis in patients with lung
cancer,” Lung Cancer, vol. 36, no. 1, pp. 71–76, 2002.

[37] D. Chen, G. Jin, Y. Wang et al., “Genetic variants in peroxi-
some proliferator-activated receptor-γ gene are associated
with risk of lung cancer in a Chinese population,” Cancer
Genetics, vol. 29, no. 2, pp. 332–337, 2008.

[38] R. Govindarajan, L. Ratnasighe, D. L. Simmons et al.,
“Thiazolidinediones and the risk of lung, prostate, and colon
cancer in patients with diabetes,” Journal of Clinical Oncology,
vol. 25, no. 12, pp. 1476–1481, 2007.

[39] “Thiazolidinediones and cardiovascular disease,” Medical
Letter on Drugs and Therapeutics, vol. 49, no. 1265, pp. 57–
58, 2007.

[40] J. D. Lewis, A. Ferrara, T. Peng et al., “Risk of bladder cancer
among diabetic patients treated with pioglitazone: interim
report of a longitudinal cohort study,” Diabetes Care, vol. 34,
no. 4, pp. 916–922, 2011.

[41] C. Piccinini, D. Motola, G. Marchesini, and E. Poluzzi,
“Assessing the association of pioglitazone use and bladder
cancer through drug adverse event reporting,” Diabetes Care,
vol. 34, no. 6, pp. 1369–1371, 2011.

[42] K. I. Inoue, Y. Kawaihito, Y. Tsubouchi et al., “Expression of
peroxisome proliferator-activated receptor (PPAR)γ in
human lung cancer,” Anticancer Research, vol. 21, no. 4, pp.
2471–2476, 2001.

[43] Y. Bren-Mattison, V. Van Putten, D. Chan, R. Winn, M.
W. Geraci, and R. A. Nemenoff, “Peroxisome proliferator-
activated receptor-γ (PPARγ) inhibits tumorigenesis by
reversing the undifferentiated phenotype of metastatic non-
small-cell lung cancer cells (NSCLC),” Oncogene, vol. 24, no.
8, pp. 1412–1422, 2005.

[44] T. H. Chang and E. Szabo, “Induction of differentiation and
apoptosis by ligands of peroxisome proliferator-activated rece-
tor γ in non-small cell lung cancer,” Cancer Research,
vol. 60, no. 4, pp. 1129–1138, 2000.

[45] K. Y. Kim, J. H. Ahn, and H. G. Cheon, “Apoptotic action
of peroxisome proliferator-activated receptor-γ activation in
human non-small-cell lung cancer is mediated via proline
oxidase-induced reactive oxygen species formation,” Mol-
ecular Pharmacology, vol. 72, no. 3, pp. 674–685, 2007.

[46] P. Shankaranarayanan and S. Nigam, “IL-4 induces apoptosis in
A549 lung adenocarcinoma cells: evidence for the pivotal
role of 15-hydroxyeicosatetraenoic acid binding to activated
peroxisome proliferator-activated receptor γ transcription
factor,” Journal of Immunology, vol. 170, no. 2, pp. 887–894,
2003.

[47] A. J. Dannenberg, N. K. Altorki, J. O. Boyle et al., “Cyclo-
oxxygenase 2: a pharmacological target for the prevention of
cancer,” Lancet Oncology, vol. 2, no. 9, pp. 544–551, 2001.

[48] Y. Bren-Mattison, A. M. Meyer, V. Van Putten et al., “Anti-
tumorigenic effects of peroxisome proliferator-activated rece-
tor-γ in non-small-cell lung cancer cells are mediated
by suppression of cyclooxygenase-2 via inhibition of nuclear factor-κB,” *Molecular Pharmacology*, vol. 73, no. 3, pp. 709–717, 2008.

[49] M. Casibang and T. W. Moody, “AH16809 antagonizes non-small cell lung cancer prostaglandin receptors,” *Lung Cancer*, vol. 36, no. 1, pp. 33–42, 2002.

[50] T. Yano, G. Zissel, J. Muller-Qernheim, S. Jae Shin, H. Satoh, and T. Ichikawa, “Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3,” *FEBS Letters*, vol. 518, no. 1–3, pp. 154–158, 2002.

[51] S. Han and J. Roman, “Suppression of prostaglandin E2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth,” *Biochemical and Biophysical Research Communications*, vol. 314, no. 4, pp. 1093–1099, 2004.

[52] S. Hazra, R. K. Batra, H. H. Tai, S. Sharma, X. Cui, and S. M. Dubinett, “Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase,” *Molecular Pharmacology*, vol. 71, no. 6, pp. 1715–1720, 2007.

[53] R. Choudhary, H. Li, R. A. Winn, A. L. Sorenson, M. C. M. Weiser-Evans, and R. A. Nemenoff, “Peroxisome proliferator-activated receptor-γ inhibits transformed growth of non-small cell lung cancer cells through selective suppression of snail,” *Neoplasia*, vol. 12, no. 3, pp. 224–234, 2010.

[54] V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer,” *Oncogene*, vol. 23, no. 1, pp. 100–108, 2004.

[55] V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPARγ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer,” *Neoplasia*, vol. 7, no. 3, pp. 294–301, 2005.

[56] P. Tontonoz, S. Singer, B. M. Forman et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 1, pp. 237–241, 1997.

[57] R. N. DuBois, R. Gupta, J. Brockman, S. B. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colon cancers,” *Carcinogenesis*, vol. 19, no. 1, pp. 49–53, 1998.

[58] A. M. Lefebvre, I. Chen, P. Desreumaux et al., “Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC(Min)/+ mice,” *Nature Medicine*, vol. 4, no. 9, pp. 1053–1057, 1998.

[59] E. Saiz, P. Tontonoz, M. C. Nelson et al., “Activators of the nuclear receptor PPARγ enhance colon polyp formation,” *Nature Medicine*, vol. 4, no. 9, pp. 1058–1061, 1998.

[60] K. Yang, K. H. Fan, S. A. Lamprecht et al., “Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice,” *International Journal of Cancer*, vol. 116, no. 4, pp. 495–499, 2005.

[61] E. Elsaesser, C. Müller, K. Koshizuka et al., “Ligands for peroxisome proliferator-activated retinoid and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 15, pp. 8806–8811, 1998.

[62] E. Saiz, J. Rosenfeld, A. Livolsi et al., “PPARγ signaling exacerbates mammary gland tumor development,” *Genes and Development*, vol. 18, no. 5, pp. 528–540, 2004.

[63] K. R. Kim, H. N. Choi, H. J. Lee et al., “A peroxisome proliferator-activated receptor gamma agonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma,” *Oncology Reports*, vol. 18, no. 4, pp. 825–832, 2007.

[64] A. Nakajima, A. Tomimoto, K. Fujita et al., “Inhibition of peroxisome proliferator-activated receptor y activity suppresses pancreatic cancer cell motility,” *Cancer Science*, vol. 99, no. 10, pp. 1892–1900, 2008.

[65] W. M. Wood, V. Sharma, K. T. Bauerle et al., “PPAR promotes growth and invasion of thyroid cancer cells,” *PPAR Research*, vol. 2011, Article ID 171765, 11 pages, 2011.

[66] L. C. Lin, S. L. Hsu, C. L. Liu, and C. M. Hsueh, “Peroxisome proliferator-activated receptor y (PPARy) plays a critical role in the development of TGFβ resistance of H460 cell,” *Cellular Signalling*, vol. 23, no. 10, pp. 1640–1650, 2011.

[67] Y.-H. Ahn, Y. Yang, D. L. Gibbons et al., “Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor y2 expression,” *Molecular and Cellular Biology*, vol. 31, no. 21, pp. 4270–4285, 2011.

[68] A. Sica and V. Bronte, “Altered macrophage differentiation and immune dysfunction in tumor development,” *Journal of Clinical Investigation*, vol. 117, no. 5, pp. 1155–1166, 2007.

[69] J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” *Cell*, vol. 124, no. 2, pp. 263–266, 2006.

[70] J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis,” *Nature Reviews Cancer*, vol. 4, no. 1, pp. 71–78, 2004.

[71] J. Wyckoff, W. Wang, E. Y. Lin et al., “A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammmary tumors,” *Cancer Research*, vol. 64, no. 19, pp. 7022–7029, 2004.

[72] M. Egeland and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” *Nature Reviews Cancer*, vol. 2, no. 3, pp. 161–174, 2002.

[73] A. Zumsteg and G. Christofori, “Corrupt policemen: inflammatory cells promote tumor angiogenesis,” *Current Opinion in Oncology*, vol. 21, no. 1, pp. 60–70, 2009.

[74] R. D. Leek and A. L. Harris, “Tumor-associated macrophages in breast cancer,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 7, no. 2, pp. 177–189, 2002.

[75] E. Y. Lin, V. Gouon-Evans, A. V. Nguyen, and J. W. Pollard, “The macrophage growth factor CSF-1 in mammary gland development and tumor progression,” *Journal of Mammary Gland Biology and Neoplasia*, vol. 7, no. 2, pp. 147–162, 2002.

[76] E. Giraudo, M. Inoue, and D. Hanahan, “An amino-bisphosphonate targets MMP-9—expressing macrophages and angiogenesis to impair cervical carcinogenesis,” *Journal of Clinical Investigation*, vol. 114, no. 5, pp. 623–633, 2004.

[77] E. Y. Lin, J. F. Li, L. Gnatosky et al., “Macrophages regulate the angiogenic switch in a mouse model of breast cancer,” *Cancer Research*, vol. 66, no. 23, pp. 11238–11246, 2006.

[78] M. Torroella-Kouri, R. Silvera, D. Rodriguez et al., “Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated,” *Cancer Research*, vol. 69, no. 11, pp. 4800–4809, 2009.

[79] B. Qian, Y. Deng, J. H. Im et al., “A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth,” *PLoS ONE*, vol. 4, no. 8, Article ID e6562, 2009.
[80] S. Gordon, “Alternative activation of macrophages,” *Nature Reviews Immunology*, vol. 3, no. 1, pp. 23–35, 2003.

[81] E. F. Redente, D. J. Orlicky, R. J. Bouchard, and A. M. Malkinson, “Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice,” *American Journal of Pathology*, vol. 170, no. 2, pp. 693–708, 2007.

[82] A. Sica, P. Larghi, A. Mancino et al., “Macrophage polarization in tumour progression,” *Seminars in Cancer Biology*, vol. 18, no. 5, pp. 349–355, 2008.

[83] J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et al., “Regulatory T cells from lung cancer patients directly inhibit autologous T lymphocytes is inhibited by peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12,14-prostaglandin J2,” *The Journal of Biological Chemistry*, vol. 274, no. 24, pp. 17042–17048, 1999.

[84] E. Y. Woo, H. Yeh, C. S. Chu et al., “Cutting edge: regulatory T cell proliferation,” *Journal of Immunology*, vol. 163, no. 1, pp. 1116–1120, 2004.

[85] E. Olaso, C. Salado, E. Egilegor et al., “Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis,” *Hepatology*, vol. 37, no. 3, pp. 674–685, 2003.

[86] T. Torimura, M. Sata, T. Ueno et al., “Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma,” *Human Pathology*, vol. 29, no. 9, pp. 986–991, 1998.

[87] T. Torimura, T. Ueno, M. Kin et al., “Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma,” *Journal of Hepatology*, vol. 40, no. 5, pp. 799–807, 2004.

[88] T. Torimura, M. Sata, T. Ueno et al., “Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma,” *Human Pathology*, vol. 29, no. 9, pp. 986–991, 1998.

[89] D. B. Panigrahy, S. Singer, L. Q. Shen et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” *Journal of Clinical Investigation*, vol. 110, no. 7, pp. 923–932, 2002.

[90] M. C. Yu, C. H. Chen, X. Liang et al., “Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice,” *Hepatology*, vol. 40, no. 6, pp. 1312–1321, 2004.

[91] C. H. Chen, L. M. Kuo, Y. Chang et al., “In vivo immune modulatory activity of hepatic stellate cells in mice,” *Hepatology*, vol. 44, no. 5, pp. 1171–1181, 2006.
[111] F. Marra, E. Efsen, R. G. Romanelli et al., “Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells,” *Gastroenterology*, vol. 119, no. 2, pp. 466–478, 2000.

[112] A. Galli, D. W. Crabb, E. Ceni et al., “Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro,” *Gastroenterology*, vol. 122, no. 7, pp. 1924–1940, 2002.

[113] T. Miyahara, L. Schrum, R. Rippe et al., “Peroxisome proliferator-activated receptors and hepatic stellate cell activation,” *The Journal of Biological Chemistry*, vol. 275, no. 46, pp. 35715–35722, 2000.

[114] J. Yu, S. Zhang, E. S. H. Chu et al., “Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro,” *International Journal of Biochemistry and Cell Biology*, vol. 42, no. 6, pp. 948–957, 2010.

[115] S. Hazra, S. Xiong, J. Wang, R. A. Rippe, V. K. K. Chatterjee, and H. Tsukamoto, “Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells,” *The Journal of Biological Chemistry*, vol. 279, no. 12, pp. 11392–11401, 2004.

[116] C. Sautès-Fridman, J. Cherfils-Vicini, D. Damotte et al., “Tumor microenvironment is multifaceted,” *Cancer and Metastasis Reviews*, vol. 30, no. 1, pp. 13–25, 2011.

[117] G. Majai, P. Gogolák, C. Ambrus et al., “PPARγ modulated inflammatory response of human dendritic cell subsets to engulfed apoptotic neutrophils,” *Journal of Leukocyte Biology*, vol. 88, no. 5, pp. 981–991, 2010.

[118] I. Waldhauer and A. Steinle, “NK cells and cancer immunosurveillance,” *Oncogene*, vol. 27, no. 45, pp. 5932–5943, 2008.

[119] X. Zhang, M. C. Rodriguez-Galán, J. J. Subleski et al., “Peroxisome proliferator-activated receptor-γ and its ligands attenuate biologic functions of human natural killer cells,” *Blood*, vol. 104, no. 10, pp. 3276–3284, 2004.

[120] W. C. Yen, R. Y. Prudente, M. R. Corpuz, A. Negro-Vilar, and W. W. Lamph, “A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours,” *British Journal of Cancer*, vol. 94, no. 5, pp. 654–660, 2006.

[121] S. E. Nissen and K. Wolski, “Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality,” *Archives of Internal Medicine*, vol. 170, no. 14, pp. 1191–1201, 2010.